348 related articles for article (PubMed ID: 33986022)
1. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30
Kerbauy LN; Marin ND; Kaplan M; Banerjee PP; Berrien-Elliott MM; Becker-Hapak M; Basar R; Foster M; Garcia Melo L; Neal CC; McClain E; Daher M; Nunez Cortes AK; Desai S; Inng Lim FW; Mendt MC; Schappe T; Li L; Shaim H; Shanley M; Ensley EL; Uprety N; Wong P; Liu E; Ang SO; Cai R; Nandivada V; Mohanty V; Miao Q; Shen Y; Baran N; Fowlkes NW; Chen K; Muniz-Feliciano L; Champlin RE; Nieto YL; Koch J; Treder M; Fischer W; Okamoto OK; Shpall EJ; Fehniger TA; Rezvani K
Clin Cancer Res; 2021 Jul; 27(13):3744-3756. PubMed ID: 33986022
[TBL] [Abstract][Full Text] [Related]
2. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
Rothe A; Sasse S; Topp MS; Eichenauer DA; Hummel H; Reiners KS; Dietlein M; Kuhnert G; Kessler J; Buerkle C; Ravic M; Knackmuss S; Marschner JP; Pogge von Strandmann E; Borchmann P; Engert A
Blood; 2015 Jun; 125(26):4024-31. PubMed ID: 25887777
[TBL] [Abstract][Full Text] [Related]
4. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
[TBL] [Abstract][Full Text] [Related]
6. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
7. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Aug; 8():96. PubMed ID: 26231785
[TBL] [Abstract][Full Text] [Related]
8. An NK-cell Therapy for CD30+ Lymphomas.
Cancer Discov; 2022 Jun; 12(6):1401-1402. PubMed ID: 35404436
[TBL] [Abstract][Full Text] [Related]
9. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
10. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
12. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
13. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.
Sundarapandiyan K; Keler T; Behnke D; Engert A; Barth S; Matthey B; Deo YM; Graziano RF
J Immunol Methods; 2001 Feb; 248(1-2):113-23. PubMed ID: 11223073
[TBL] [Abstract][Full Text] [Related]
16. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
[TBL] [Abstract][Full Text] [Related]
17. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
18. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.
Reiners KS; Kessler J; Sauer M; Rothe A; Hansen HP; Reusch U; Hucke C; Köhl U; Dürkop H; Engert A; von Strandmann EP
Mol Ther; 2013 Apr; 21(4):895-903. PubMed ID: 23459515
[TBL] [Abstract][Full Text] [Related]
19. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
[TBL] [Abstract][Full Text] [Related]
20. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
